The FDA said the fake Avastin was the first U.S. case involving a counterfeit version of a cancer drug meant to be administered in physicians' offices.
Meanwhile, the Joint Commission--one of three regulators of office-surgery facilities in the U.S.--estimates that only 5% of the nearly 40, 000 physicians' offices where surgeries are performed have the necessary accreditation.